Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or without inhibitors.

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

with hemophilia A or B with or without factor VIII or IX inhibitors. The approval is based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as measured ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent ...

with hemophilia A or B with or without factor VIII or IX inhibitors. The approval is based on data from the ATLAS phase 3 studies that demonstrated clinically meaningful bleed protection as ...

with or without factor VIII or IX inhibitors (neutralizing antibodies). "Today's approval of Qfitlia is significant for patients with hemophilia because it can be administered less frequently than ...

Scientists at the University of Bath have developed the first irreversible peptide inhibitors that block the cancer-driving protein cJun, using a new screening method that shows promise for targeting ...

NA activity was determined in 96-well white U-bottom microplates (Greiner bio-one GmbH, Frickenhausen, Germany) using the CL-based NA-Star assay (NA-Star Influenza Neuraminidase Inhibitor ...